MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer

Inclusion Criteria: * Patients must have histologically-confirmed operable invasive breast cancer and have undergone core needle biopsy with an anticipated surgical resection for residual disease after enrollment * Patients must have clinical stage I-III invasive breast (invasive tumor must be clinically at least \>= T1c by radiograph or palpation) * Patients must have available tissue from core biopsies for biomarker assessment; it is recommended that at least 4 cores be performed with 12 gauge (or smaller gauge) needles; this includes cores underneath ultrasound-guidance * Patients are planning to undergo surgical treatment with either segmental resection or total mastectomy (required: 2 doses of weekly MK-2206 prior to surgery; the first dose will be at day -9 \[+/- 1 day\] and second dose at day -2 \[+/- 1 day\] in relation to surgery \[day 0\]) * Patients may have a history of contralateral breast cancer, provided there is no evidence of recurrence of the initial primary breast cancer * Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 (Karnofsky \>= 80%) * Leukocytes \>= 3,000/ul within 28 days of registration * Platelets \>= 100,000 /uL within 28 days of registration * Hemoglobin (Hgb) \>= 9 g/dL within 28 days of registration * Creatinine =\< 1.5 x upper limit of normal (ULN) within 28 days of registration * Prothrombin time (PT), partial thromboplastin time (PTT) =\< 1.2 x ULN within 28 days of registration * Total bilirubin =\< 1.5 x ULN within 28 days of registration * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \< 2.5 x ULN within 28 days of registration * Patients of childbearing potential must have a negative serum or urine pregnancy test beta-human chorionic gonadotropin (β-hCG) within 72 hours prior to receiving the first dose of study medication * Women of childbearing potential and men must use two forms of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, the patient should inform the treating physician immediately * Patient must be able to swallow oral tablets * Ability to understand and the willingness to sign a written informed consent document * Patients must agree to biomarker assessment of pre-treatment diagnostic core biopsy tissue and the surgical resection tissue (i.e. excision or mastectomy); also, must agree to pre- and post-treatment fasting blood biomarker collection Exclusion Criteria: * Patients may not have any known evidence of distant metastatic disease (i.e., lung, liver, bone, or brain metastases) or locally recurrent breast cancer * Patients with inflammatory breast cancer are not eligible * Patients with prior chemotherapy or radiation therapy within 6 months of study entry are not eligible (i.e. patient who have received neoadjuvant therapy are not eligible) * Patients may not be receiving any other investigational agents, including other inhibitors of PI3K, Akt, or mammalian target of rapamycin (mTOR) * Men diagnosed with breast cancer * Patients may not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to MK-2206 used in the study * Patients with known diabetes which is poorly controlled diabetes (hemoglobin A1c \[HBA1C\] \>= 8%) should be excluded; if patient is taking metformin, must have been taking this medication for \> 3 months, as metformin is thought to impact PI3K/Akt signaling * Baseline corrected QT interval (QTc) \> 470 msec will exclude patients from entry on study; patients with a baseline bundle branch block will be excluded * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MK2206 * Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible